[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-cirrhotic-portal-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-cirrhotic-portal-hypertension":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,85,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100499384","freiburg-tips-registry-100499384",false,"NCT05782556","Freiburg TIPS Registry","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study","FRETIR","Inclusion Criteria:\n\n* Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","ALL","18 Years","100 Years",{"count":21,"type":22},2000,"ESTIMATED","12 Months","OBSERVATIONAL","Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.\n\nClinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum\u002Fplasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.",[27,28,29,30,31,32],"Liver Cirrhosis","Portal Hypertension","Non-Cirrhotic Portal Hypertension","Budd Chiari Syndrome","Portal Vein Thrombosis","Portal Systemic Shunt",[34,35,29,36,37],"Liver cirhosis","Transjugular intrahepatic portosystemic shunt","Prognosis","Outcome","RECRUITING","2026-04-27",{"date":41,"type":42},"2026-05-01","ACTUAL",{"date":44,"type":42},"2023-01-01",{"date":46,"type":22},"2034-06-30",{"name":48,"class":49},"University Hospital Freiburg","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100625617","hepatic-venous-pressure-gradient-versus-endoscopic-ultrasound-guided-portal-pressure-gradient---comparative-analysis-hepca-100625617","NCT07424963","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis","HEPCA","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment; signed informed consent\n* Clinical indication for HVPG measurement and\u002For transjugular liver biopsy for chronic advanced liver disease\n\nExclusion Criteria:\n\n* Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes mellitus with severe complications)\n* Pregnancy\n* Estimated patient non-compliance and\u002For not signing of the informed consent\n* Documented iodine contrast dye allergy\n* Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction\n* Ascites Grade 3\n* Biliary obstruction\n* Anticoagulation or antiplatelet therapy, which cannot be discontinued\n* INR \\> 1.5 and\u002For platelet count \\\u003C 50,000\u002Fµl\n* Hepatocellular carcinoma in the left lobe of the liver\n* Surgically altered upper gastrointestinal tract anatomy\n* State after transjugular intrahepatic portosystemic shunt\n* State after liver transplantation","75 Years",{"count":61,"type":22},40,"INTERVENTIONAL",[64],"NA","The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement.\n\nThe primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy.\n\nParticipants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.",[67,28,68,29,69,70],"Cirrhosis","EUS","HVPG","Hepatic Venous Pressure Gradient",[69,72,73,74],"EUS-PPG","portal hypertension","liver cirrhosis","2026-02-16",{"date":77,"type":42},"2026-02-20",{"date":79,"type":42},"2025-05-30",{"date":81,"type":22},"2028-12-31",{"name":83,"class":49},"Military University Hospital, Prague",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":50},"100554539","non-invasive-tools-for-psvd-diagnosis-100554539","NCT06500403","Non-invasive Tools for PSVD Diagnosis","Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study","Inclusion Criteria:\n\n1. Received platinum chemotherapy for organ tumors;\n2. Ages 18-80;\n3. sign the informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Liver pathology suggested cirrhosis;\n2. Underwent liver transplantation;\n3. Combined with hepatocellular carcinoma exceeding Milan criteria;\n4. Complicated with severe heart, kidney, or lung failure;\n5. Pregnant or lactating women;\n6. Data is seriously missing;\n7. Patients were judged not suitable for participation in this study by the researchers.","80 Years",{"count":94,"type":22},1000,"Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.",[29,97],"Porto-Sinusoidal Vascular Diseases","2024-07-08",{"date":100,"type":42},"2024-07-15",{"date":102,"type":42},"2024-02-28",{"date":104,"type":22},"2029-12-31",{"name":106,"class":49},"Nanfang Hospital, Southern Medical University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":50},"100406890","predicting-acute-on-chronic-liver-failure-after-surgical-intervention-in-chronic-liver-disease-100406890","NCT04578301","Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease","PERSEVERE","Inclusion Criteria:\n\n* Male or female adult (≥18 years) patient\n* With or without liver cirrhosis (diagnosed either histologically or by a combination of clinical, laboratory and radiological signs)\n* Or Non-cirrhotic portal hypertension\n* Non-pregnant, non-lactating females\n* Ability to understand the patient information and to personally sign and date the informed consent to participate in the study\n* The patient is co-operative and available for the entire study\n* Provided written informed consent\n* Indication for surgical intervention\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Patients undergoing surgery as form of palliative cancer therapy\n* Presence or history of severe extra-hepatic diseases\n* HIV-positive patients\n* Previous liver or other transplantation\n* Patients with acute or subacute liver failure without underlying cirrhosis\n* Patients who decline to participate\n* Physician´s denial (e.g. the investigator considers that the patient will not follow the protocol scheduled)",{"count":115,"type":22},200,"Prospective, observational study to define precipitants and predictors of development of Acute-on-Chronic Liver Failure (ACLF) after surgical interventions, allowing to develop a risk stratification for elective procedures in cirrhotic patients. As well as identifying molecular mechanisms of post-interventional ACLF and thus preparing the ground for development of new therapeutic approaches.",[27,28,118,119,29],"Surgery","Acute-On-Chronic Liver Failure",[121,119,27,28,118,29],"ACLF","2022-05-17",{"date":124,"type":42},"2022-05-18",{"date":126,"type":42},"2020-09-22",{"date":128,"type":22},"2026-12-31",{"name":130,"class":49},"University Hospital, Bonn","Non Cirrhotic Portal Hypertension"]